Clinical Trials for Esophageal Cancer

201808178

A Phase II study of chemotherapy and immune checkpoint blockade with Pembrolizumab in the perioperative and maintenance treatment of locoregional gastric or GE junction adenocarcinoma. Phase II (Cancer Control) Principal Investigator Lim, Kian-Huat Disease Site…

201909019

Phase I Study of Radiation Dose Intensification with Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer Phase I Principal Investigator Badiyan, Shahed Disease Site Esophagus; Stomach Learn more…

201912097

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors Phase I Principal Investigator Adkins, Douglas Disease Site Anus; Bones and Joints;…

202001128

A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors Phase Early Phase I (Cancer Control) Principal Investigator Weiss,…

202006133

A phase 1b dose escalation study of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy for HER2+ gastrointestinal cancers

202012018

Phase II study of short course FOLFOX chemotherapy with either Nivolumab or Nivolumab + Radiation in the first line treatment of metastatic or unresectable gastroesophageal cancers (BMS Protocol CA209-76L) Phase II Principal Investigator Lim, Kian-Huat…

202101058

Phase III Randomized Trial of Proton Beam Therapy(PBT) versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer Phase III Principal Investigator Badiyan, Shahed Disease Site Esophagus; Other Digestive Organ Learn more about…

202102071

A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma Phase II/III Principal Investigator Lim, Kian-Huat Disease Site Esophagus; Other Digestive Organ Learn more about this study…

202104080

A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of thorium-227 labeled antibody-chelator conjugate BAY 2701439, in participants with advanced HER2-expressing tumors Phase I Principal Investigator Wahl, Richard…

202105140

Phase 1/1B study of DS-8201a in combination with ATR Inhibition (AZD6738) in advanced solid tumors with HER2 expression (DASH Trial) Phase I Principal Investigator Grierson, Patrick Disease Site Breast; Colon; Corpus Uteri; Esophagus; Lip, Oral…

202105147

Phase 1/1b Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI Malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers Phase I Principal Investigator Grierson, Patrick Disease Site Esophagus; Stomach Learn…

202201030

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936-0901 (Anti-ADAM9 Antibody Drug Conjugate) in Patients with Advanced Solid Tumors Phase I/II (Cancer Control) Principal Investigator Davis, Andrew; Davis, Andrew Disease Site Breast; Colon;…